OAB-052: Isatuximab plus pomalidomide/low-dose dexamethasone versus pomalidomide/low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (ICARIA-MM): final overall survival analysis
Titel:
OAB-052: Isatuximab plus pomalidomide/low-dose dexamethasone versus pomalidomide/low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (ICARIA-MM): final overall survival analysis
Auteur:
Richardson, Paul Perrot, Aurore San-Miguel, Jesus Beksac, Meral Špička, Ivan Leleu, Xavier Schjesvold, Fredrik Moreau, Philippe Dimopoulos, Meletios A. Huang, Jeffrey Shang-Yi Minarik, Jiri Cavo, Michele Prince, H Miles Malinge, Laure Dubin, Franck Morisse, Mony Anderson, Kenneth